Global /Sweden /Healthcare /Biotechnology /BIOVIC-B

Biovica International AB (publ)

BIOVIC-B

• STO: BIOVIC-B • Delayed

0.3130SEK -2.2%

0.0331 USD

As of 11 June 2026, Biovica International AB (publ) has a market cap of $9.84M USD, ranking #41345 globally and #649 in Sweden. It ranks #3670 in the Healthcare sector, and #719 in the Biotechnology industry.

Global Rank

41345

Country Rank

649

Sector Rank

3670

Industry Rank

719

Key Stats

Market Cap

$9.84MUSD

93.41M SEK

Enterprise Value

$1.06MUSD

10.02M SEK

Revenue (TTM)

$1.15MUSD

10.93M SEK

EBITDA (TTM)

-$7.72MUSD

-73.03M SEK

Net Income (TTM)

-$7.53MUSD

-71.51M SEK

PS Ratio

8.6

PB Ratio

0.9

Company Profile

Country (HQ)

Sweden

Sector

Healthcare

Industry

Biotechnology

CEO

Anders Rylander open_in_new

Employees

Founded

2008

Website

biovica.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.2%	-7.9%	-13%	-26%	-42%	-15%	-57%	-96%	-99%

Upcoming Earnings

Earnings Date

Wed, Jun 17

News

Markets

Exchange	Ticker	Price	Quotes
Nasdaq Stockholm (STO) MIC: XSTO PRIMARY	BIOVIC-B Biovica International AB ISIN: SE0008613731 Shares Out.: Shares Outstanding: 277.487M¹ Shares Float: 266.33M² TV: TradingView: OMXSTO: BIOVIC_B SA: Stock Analysis: STO: BIOVIC.B YF: Yahoo Finance: BIOVIC-B.ST GF: Google Finance: STO: BIOVIC-B BA: Barron's: BIOVIC.B MS: Morningstar: XSTO: BIOVIC-B	0.3130 SEK	TV: TradingView: OMXSTO: BIOVIC_B SA: Stock Analysis: STO: BIOVIC.B YF: Yahoo Finance: BIOVIC-B.ST GF: Google Finance: STO: BIOVIC-B BA: Barron's: BIOVIC.B MS: Morningstar: XSTO: BIOVIC-B
Frankfurt Stock Exchange (FRA) MIC: XFRA	9II Biovica International AB ISIN: SE0008613731 TV: TradingView: FWB: 9II SA: Stock Analysis: FRA: 9II YF: Yahoo Finance: 9II.F GF: Google Finance: FRA: 9II BA: Barron's: 9II MS: Morningstar: XFRA: 9II	0.0002 EUR	TV: TradingView: FWB: 9II SA: Stock Analysis: FRA: 9II YF: Yahoo Finance: 9II.F GF: Google Finance: FRA: 9II BA: Barron's: 9II MS: Morningstar: XFRA: 9II

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Biovica International AB (publ)

Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.

Similar Companies

Industry: Biotechnology (Sweden)

Name	Market Cap (USD) diff.	PE	Country
Vimian Group AB (publ) STO: VIMIAN	$1.57B 14.9B SEK 16K%	43.7	Sweden
BioInvent International AB (publ) STO: BINV	$149.35M 1.42B SEK 1K%	-	Sweden
BICO Group AB (publ) STO: BICO	$139.89M 1.33B SEK 1K%	-	Sweden
Cinclus Pharma Holding AB (publ) STO: CINPHA	$59.6M 565.9M SEK 506%	-	Sweden
Intervacc AB (publ) STO: IVACC	$41.28M 391.94M SEK 320%	-	Sweden
Bio-Works Technologies AB (publ) NGM: BIOWKS	$32.67M 310.2M SEK 232%	-	Sweden

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 2M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 2M%	19.0	United States
argenx SE EBR: ARGX	$47.8B 41.39B EUR 486K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.82B 68.19T KRW 455K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.25B 60.27B AUD 429K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.17B 33.71B CHF 429K%	37.2	Switzerland

chevron_leftBack